WHO Looking at Ivermectin within Weeks as COVID-19 for Early Onset Treatment

WHO Looking at Ivermectin within Weeks as COVID-19 for Early Onset Treatment

TrialSite reports to the TSN community a recent World Health Organization (WHO) video from today. The panel was asked by a reporter about the use of Ivermectin in early onset care for SARS-CoV-2, the virus behind COVID-19. Referring to the U.S.-based Front Line COVID-19 Critical Care Alliance (FLCCC), proponents for the use of the well-known, economical drug used in many developing countries to combat parasites, WHO declared that they are presently evaluating the data and expect to form guidance within 4 to 6 weeks. WHO—the world is watching.

The WHO representative explained that the process takes time as they must meticulously analyze data given the perception at least as to the questions involving the quality of the underlying clinical trials, many sponsored and conducted in developing nations such as Bangladesh, India, Argentina, Iraq, and Egypt. However, the three leading meta-analyses, authored in the United Kingdom by Dr. Andrew Hill as commissioned by UnitAid, as well as Dr. Tess Lawrie not to mention the physicians from the FLCCC suggest there is more than enough evidence. TrialSite does not state that Dr. Hill privately suggests the evidence is there but apparently his...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee